Analyst Reco. Pulmonx Corporation

Equities

LUNG

US7458481014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
8.78 ^USD	-1.57%		-1.46%	-31.14%

May. 01	Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M	MT
May. 01	Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16	Feb. 23	MT
Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating	Feb. 22	MT
Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating	Feb. 22	MT
Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating	Feb. 22	MT
Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating	Feb. 22	MT
Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating	Feb. 22	MT
Craig-Hallum Initiates Pulmonx at Buy With $18 Price Target	23-09-05	MT
Citigroup Raises Price Target on Pulmonx to $16 From $14, Maintains Buy Rating	23-07-11	MT
Piper Sandler Adjusts Pulmonx's Price Target top $15 From $13, Keeps Overweight Rating	23-05-03	MT
Morgan Stanley Adjusts Pulmonx's Price Target to $14 From $11, Keeps Equalweight Rating	23-05-03	MT
Citigroup Adjusts Pulmonx Price Target to $13 From $12, Maintains Buy Rating	23-04-03	MT
Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10	23-02-27	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating	23-02-23	MT
Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating	23-02-23	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $9.50 From $14, Maintains Equalweight Rating	23-01-06	MT
BofA Securities Downgrades Pulmonx to Underperform From Neutral With $8 Price Target	23-01-03	MT
Wells Fargo Cuts Price Target on Pulmonx to $6 From $13.50, Maintains Equalweight Rating	22-12-12	MT
Citigroup Upgrades Pulmonx to Buy From Neutral, Adjusts Price Target to $10 From $14	22-12-12	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $14 From $19, Maintains Equal-Weight Rating	22-11-07	MT
Piper Sandler Adjusts Price Target on Pulmonx to $13 From $25, Maintains Overweight Rating	22-11-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pulmonx Corporation

Equities

LUNG

US7458481014

Analyst Reco.

Filters